> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rinvoq Shows Promise in Arteritis: AbbVie
- URL: https://www.fdaweb.com/rinvoq-shows-promise-in-arteritis-abbvie/
- Published: 2024-04-18T12:00:00.000Z
- Updated: 2026-09-14T14:28:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156809

AbbVie is announcing what it calls “positive” top-line results from SELECT-GCA, a Phase 3, placebo-controlled study, that showed the company’s arthritis drug Rinvoq (upadacitinib) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA). “In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regimen achieved sustained remission compared to 29 percent of patients receiving placebo in combination with a 52-week steroid taper regimen (p=0.0019),” the company says.

GCA is described as an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium arteries. “GCA generally impacts elderly patients older than 50 years, most commonly between the ages of 70 and 80 years,” the company says.

Regarding safety, the company says the safety profile of upadacitinib was generally consistent with that observed in approved indications. Discontinuations due to adverse events occurred in 15% of patients in the upadacitinib 15 mg group and 21% in the placebo group, it says.